Baseline demographics and disease characteristics
| All BARI RA (Phase 3) (n=2890) | |
| Age, years | 52.9 (12.3) |
| Female, n (%) | 2269 (78.5) |
| Region, n (%) | |
| Asia* (excluding Japan) | 226 (7.8) |
| South America† | 658 (22.8) |
| European Union | 670 (23.2) |
| Japan | 371 (12.8) |
| North America‡ | 606 (21.0) |
| Rest of the world | 359 (12.4) |
| Disease duration (from diagnosis), years | 7.7 (8.2) |
| Corticosteroid use at baseline, n (%) | 1492 (51.6) |
| Methotrexate use at baseline, n (%) | 2139 (74.0) |
| Tender joint counts (68 joints) | 25.1 (14.4) |
| Swollen joint counts (66 joints) | 15.3 (9.1) |
| CDAI | 38.4 (12.7) |
| DAS28-CRP | 5.8 (0.9) |
| Baseline serology,§ n | |
| HBsAg−; HBsAb−/HBcAb− | 2249 |
| HBsAg−; HBsAb+/HBcAb− | 363 |
| HBsAg−; HBsAb+/HBcAb+ | 255 |
| HBsAg−; HBsAb−/HBcAb+ | 14 |
Values are mean (SD) unless otherwise stated.
*China, Taiwan, South Korea.
†Central/South America and Mexico.
‡USA/Canada (including Puerto Rico).
§Total number of patients with baseline serology is n=2881 owing to missing data for nine patients (eight missing surface antibody and one missing core antibody data).
BARI, baricitinib; CDAI, clinical disease activity index; DAS28-CRP, Disease Activity Score 28 – C-reactive protein; HBcAb, hepatitis B virus core antibody; HBsAb, hepatitis B virus surface antibody; HBsAg, hepatitis B virus surface antibody; RA, rheumatoid arthritis.